Spero Therapeutics (SPRO) Prepaid Assets (2016 - 2026)
Spero Therapeutics' (SPRO) quarterly Prepaid Assets came in at $1.4 million in Q1 2026, down 7.04% YoY from $1.5 million in Q1 2025, and down 11.93% on a QoQ basis from $1.6 million in Q4 2025.
Spero Therapeutics (SPRO) Prepaid Assets (2016 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 11 years of Prepaid Assets data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Prepaid Assets fell 7.04% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.4 million (down 7.04% YoY) and the FY2025 annual result came in at $1.6 million, down 14.5% from the prior year.
- Prepaid Assets slipped to $1.4 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $8.7 million in Q1 2022 to a low of $1.2 million in Q3 2025.
- A 5-year average of $3.4 million and a median of $3.2 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets sank 74.2% — and 2023, when it soared 263.44%.
- Tracing SPRO's Prepaid Assets over 5 years: stood at $3.4 million in 2022, then gained by 23.65% to $4.2 million in 2023, then sank by 54.26% to $1.9 million in 2024, then slipped by 14.5% to $1.6 million in 2025, then dropped by 11.93% to $1.4 million in 2026.
- The last three Prepaid Assets figures came in at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Spero Therapeutics | 70.72 Mn | 19.95 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 785,000.00 |
| Mar 31, 2026 | 1.44 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.30 Mn |
| Mar 31, 2025 | 1.55 Mn |
| Dec 31, 2024 | 1.91 Mn |
| Sep 30, 2024 | 2.06 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Mar 31, 2024 | 3.67 Mn |
| Dec 31, 2023 | 4.18 Mn |
| Sep 30, 2023 | 5.41 Mn |
| Jun 30, 2023 | 8.57 Mn |
| Mar 31, 2023 | 3.54 Mn |
| Dec 31, 2022 | 3.38 Mn |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 4.98 Mn |
| Mar 31, 2022 | 8.75 Mn |
| Dec 31, 2021 | 8.83 Mn |
| Sep 30, 2021 | 5.77 Mn |